IP Library Granted Patent US 9,427,605
Granted Patent B2
US 9,427,605 · App. 11/909,152 · Granted Aug 30, 2016

Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,427,605
App. No.
11/909,152
Granted
Aug 30, 2016
Kind
B2
Abstract

A cosmetic treatment device includes a nitric oxide (NO) eluting polymer, a carrier, and a proton donor enclosed in a container that keeps the proton donor separate from the nitric oxide eluting polymer until the device is used. When the container is opened, proton donor contacts the polymer, causing the elution of nitric oxide from the polymer.

Claims (31)

1. A cosmetic treatment device configured for delivering nitric oxide (NO) to a treatment site of a body, wherein said device comprises:

a NO eluting polymer, a carrier material, and a container containing a proton donor;

wherein the NO eluting polymer and proton donor are separated by the container such that, upon the release of proton donor from the container, the NO eluting polymer and proton donor come into contact and thereby the elution of NO from the NO eluting polymer is activated and NO is delivered to the treatment site wherein the container containing a proton donor is a container selected from the group consisting of: a bag, a sponge, and a micro capsule.

2. The device according to claim 1 , wherein the device is configured such that said elution of NO from said device in use is directed towards said treatment site.

3. The device according to claim 2 , wherein said device comprises:

a first membrane permeable to nitric oxide on a first side of the device and

a second membrane, said second membrane having a lower permeability to nitric oxide than said first membrane on a second side of said device, wherein

in use after activation of NO release from the NO eluting polymer, the first side of said device is oriented towards the treatment site and the second side of the device is oriented away from the treatment site.

4. The device according to claim 1 , wherein said NO eluting polymer comprises one or more functional groups selected from the group consisting of diazeniumdiolate groups, S-nitrosylated groups, and O-nitrosylated groups.

5. The device according to claim 4 , wherein said NO eluting polymer is linear poly (ethylenimine) diazeniumdiolate loaded with NO to form said diazeniumdiolate functional groups.

6. The device according to claim 1 , wherein said nitric oxide eluting polymer is selected from the group consisting of amino cellulose, amino dextrans, chitosan, aminated chitosan, polyethyleneimine, PEI-cellulose, polypropyleneimane, polybutyleneimine, polyurethane, poly(butanediol spermate), poly(iminocarbonate), polypeptide, Carboxy Methyl Cellulose (CMC), polystyrene, poly(vinyl chloride), polydimethylsiloxane, and any combinations of these.

7. The device according to claim 1 , wherein said device has a form selected from the group consisting of a condom, a sheath, a sock, a patch, a pad, a tape, and a coating.

8. The device according to claim 7 , wherein said form comprises a form material selected from the group consisting of polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), CMC, protein based polymers, gelatin, biodegradable polymers, cotton, and latex, or and any combinations of these.

9. The device according to claim 1 , wherein said proton donor is selected from the group consisting of water, methanol, ethanol, propanols, butanols, pentanols, hexanols, phenols, naphthols, polyols, phosphates, succinates, carbonates, acetates, formates, propionates, butyrates, fatty acids, and amino acids, and any combinations of these.

10. The device according to claim 1 , wherein said device is partly disintegrable when subjected to said proton donor.

11. The device according to claim 1 , wherein said NO eluting polymer comprises silver.

12. The device according to claim 1 , wherein said NO eluting polymer is in a form selected from the group consisting of fibers, nano-particles and micro-spheres.

13. The device according to claim 12 , wherein said form is provided as a substance selected from the group consisting of gel, cream, foam, and hydrogel, and combinations thereof.

14. The device according to claim 12 , wherein said nano-particles or microspheres are integrated with a material selected from the group consisting of polyethylene, polypropylene, polyacrylonitxile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), CMC, protein based polymers, gelatine, biodegradable polymers, cotton, latex, and any combinations of these.

15. The device according to claim 1 , wherein said carrier material is selected from the group consisting of polyethylene, polypropylene, polyacrylonitrile, polyurethane, polyvinylacetates, polylacticacids, starch, cellulose, polyhydroxyalkanoates, polyesters, polycaprolactone, polyvinylalcohol, polystyrene, polyethers, polycarbonates, polyamides, polyolefins, poly(acrylic acid), Carboxy Methyl Cellulose (CMC), protein based polymers, gelatin, biodegradable polymers, cotton, latex, and any combinations of these.

16. The device according to claim 1 , wherein said carrier material is a hydrogel.

17. The device according to claim 1 , wherein the device comprises a syringe having two separate containers, wherein a first container contains a proton donor- and a second container contains the nitric oxide eluting polymer, wherein the syringe-type device is configured to provide admixing upon administration to said site.

18. The device according to claim 1 , wherein said nitric oxide eluting polymer comprises a secondary amine in a backbone of the polymer or a secondary amine as a pendant of the polymer.

19. The device according to claim 18 , wherein a positive ligand is located on an atom adjacent to the secondary amine.

20. The device according to claim 1 , and further comprising an absorbent agent.

21. The device according to claim 20 , wherein said absorbent agent is selected from the group consisting of polyacrylate, polyethylene oxide, CMC, microcrystalline cellulose, cotton, or starch, or and any combinations thereof.

22. The device according to claim 1 , and further comprising a cation stabilizing the nitric oxide eluting polymer.

23. The device according to claim 22 , wherein said cation is selected from the group consisting of Na + , K + , Li+, Be 2+ , Ca 2+ , Mg 2+ , Ba 2+ , Sr 2+ , and any combinations thereof.

24. The device according to claim 1 , wherein treatment site is affected by a cosmetically treatable condition selected from the group consisting of chronological age, warts, dryness, loss of elasticity, hyperseborrhea, dull complexion, dilation of the pores, hair loss, age spots, wrinkles, acne, and scarring.

25. The device according to claim 1 , and further comprising a cosmetic agent selected from the group consisting of a desquamating agent, a moisturizer, a depigmenting agent, a propigmenting agent, an anti-glycation agent, a 5 -alphareductase inhibitor, a lysyl hydroxylase inhibitor, a prolyl hydroxylase inhibitor, an agent for stimulating the synthesis of dermal or epidermal macromolecules, an agent for preventing the degradation of dermal or epidermal macromolecules, an agent for stimulating keratinocyte proliferation and/or differentiation, a muscle relaxant, an antimicrobial agent, a tensioning agent, an anti-pollution agent, a free-radical scavenger, and any combination of these.

26. The device according to claim 1 , wherein the device is configured, when in use, to deliver a dose of NO to the treatment site of between 0.001 and 5000 ppm NO.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2025
From: LNHC, INC.
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 071481/0040 →